Neurocrine Biosciences
NBIX
#1321
Rank
HK$134.29 B
Marketcap
HK$1,327
Share price
0.17%
Change (1 day)
13.78%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2023 (TTM): HK$15.32

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is HK$54.67. In 2022 the company made an earnings per share (EPS) of HK$12.63 an increase over its 2021 EPS that were of HK$7.45.

EPS history for Neurocrine Biosciences from 1997 to 2023

Annual EPS

Year EPS Change
2023 (TTM)HK$15.3221.33%
2022HK$12.6369.47%
2021HK$7.45-78.21%
2020HK$34.20990%
2019HK$3.1481.82%
2018HK$1.73-113.5%
2017-HK$12.790.62%
2016-HK$12.7157.28%
2015-HK$8.0825.61%
2014-HK$6.4318.84%
2013-HK$5.41-1085.71%
2012HK$0.55-89.71%
2011HK$5.33-500%
2010-HK$1.33-86.92%
2009-HK$10.20-43.48%
2008-HK$18.04-57.8%
2007-HK$42.7592.58%
2006-HK$22.20371.67%
2005-HK$4.71-52.76%
2004-HK$9.9636.56%
2003-HK$7.30-70%
2002-HK$24.32118.31%
2001-HK$11.148.4%
2000-HK$10.2848.86%
1999-HK$6.90-20%
1998-HK$8.63-479.31%
1997HK$2.27

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
HK$5.57-89.81%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
HK$45.90-16.05%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
HK$242.32 343.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
-HK$1.57-102.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-HK$15.92-129.12%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
HK$40.63-25.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
-HK$59.22-208.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
HK$12.00-78.06%๐Ÿ‡ฌ๐Ÿ‡ง UK